Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06439706 · ClinicalTrials.gov registry record · NA
HPV Self-sampling for Underscreened Latinas
A NA study of Uterine Cervical Neoplasm, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
- 1
- Study location
NCT06439706: Completed NA study of Uterine Cervical Neoplasm, sponsored by Fox Chase Cancer Center.
NCT06439706 is a NA study of Uterine Cervical Neoplasm that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 108 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06439706, a NA study of Uterine Cervical Neoplasm, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn if women of Hispanic/Latina ethnicity are willing to self-collect a cervico-vaginal sample for HPV testing. The main question the study will answer is: • Does a brief educational intervention increase the feasibility and acceptability of HPV self-sampling among Hispanic/Latina women? The study team will compare whether including a brief educational intervention with a mailed HPV self-sampling kit is more acceptable than receiving a mailed HPV self-sampling kit alone. Participants will be asked to complete surveys at study entry (baseline) and then randomized to receive only the HPV self-sampling kit, or the kit plus a small group education that meets with a bilingual health educator. Participants will then be contacted about one-month later to complete a follow-up survey. The study team will also measure the number of participants in each group who self-collect a sample and mail it in for HPV testing.
Primary Outcome
The number of participants in the intervention arm who attend at least one session
Conditions Studied
Interventions
- BEHAVIORAL HPV Self-Sampling
- BEHAVIORAL Group Education
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2024-09-30 |
| Phase | NA |
What the finished NCT06439706 record still lists
NCT06439706 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Uterine Cervical Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which HPV Self-Sampling is the first listed.
NCT06439706 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06439706 about?
NCT06439706 is a clinical study titled "HPV Self-sampling for Underscreened Latinas". The goal of this study is to learn if women of Hispanic/Latina ethnicity are willing to self-collect a cervico-vaginal sample for HPV testing. The main question the study will answer is: • Does a brief educational intervention increase the feasibility and acceptability of HPV self-sampling among Hi...
What is the current status of trial NCT06439706?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2023-10-04. Estimated completion is 2024-09-30.
What conditions does trial NCT06439706 study?
This clinical trial studies the following conditions: Uterine Cervical Neoplasm.
What interventions are being tested in trial NCT06439706?
The interventions under investigation include: HPV Self-Sampling (BEHAVIORAL), Group Education (BEHAVIORAL).
Who is sponsoring clinical trial NCT06439706?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06439706 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06439706's enrollment target sits among peer trials
108 825th of 2000 higher than 1,171 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI